BLACKLEDGER Selling Watch: IQ, HUT, NTLA
BLACKLEDGER's latest selling watch update tracks IQ, HUT, NTLA, TSLA, COIN, ABOS from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Selling Watch Data
The dedicated feed category for this update is Selling. The latest public scan timestamp is 2026-10-15T08:00:10.158644+00:00.
- IQ (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- HUT (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- NTLA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- TSLA (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- COIN (stock): Bear public bias, Extended, public score 9.0/10, status: Paper trading research.
- ABOS (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
- HIVE (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
- EVGO (stock): Bear public bias, Extended, public score 8.0/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
IQ Public Research Bio
Name: iQIYI, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
iQIYI, Inc. provides online entertainment video services in the People's Republic of China. The company operates a platform that provides a collection of internet video content, such as professionally produced content licensed from professional content providers and self-produced content. It also engages in the production, aggregation, and distribution of online long-form videos, micro dramas, micro animations, micro variety shows, edited video clips, and video blogs; and provision of experience services, online mobile games, comics, and others. In addition, the company provides membership, online brand and performance-based advertising, and content distribution services. Further, it is involved in the talent agency and IP licensing activities. The company was formerly known as Qiyi.com, Inc. and changed its name to iQIYI, Inc. in November 2017. The company was incorporated in 2009 and is based in Beijing, the People's Republic of China
- Latest public price/reference: $0.951
- Public market capitalization: $918.03M
- Recent public volume/reference: 10.35M
- One-month public movement: 10.58%
- Sector/category: Communication Services
Why IQ Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
HUT Public Research Bio
Name: Hut 8 Corp.. Market class: stock. Public bias: Bear. Public tier: Extended.
Hut 8 Corp., together with its subsidiaries, operates as an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel energy-intensive use cases in the United States and Canada. It operates through Power, Digital Infrastructure, Compute, and Other segments. The company offers managed services for energy infrastructure development, such as site design, procurement, and construction management; software automation, process design, personnel hiring, and team training; utilities contracts, hosting operations, and customer management; energy portfolio optimization and strategic initiatives; and finance, accounting, and safety services. It also engages in the operation of compute infrastructure; and provision, hosting, monitoring, troubleshooting, repair, maintenance, and sale of mining equipment. In addition, the company offers Bitcoin mining; data center and cloud infrastructure services, inc
- Latest public price/reference: $74.87
- Public market capitalization: $9.23B
- Recent public volume/reference: 12.84M
- One-month public movement: -7.2%
- Sector/category: Financial Services
Why HUT Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
NTLA Public Research Bio
Name: Intellia Therapeutics, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioed[redacted]. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeu
- Latest public price/reference: $11.43
- Public market capitalization: $1.60B
- Recent public volume/reference: 5.43M
- One-month public movement: -10.42%
- Sector/category: Healthcare
Why NTLA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
TSLA Public Research Bio
Name: Tesla, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. The company operates in two segments, Automotive; and Energy Generation and Storage. The company offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty maintenance services and collision, automotive insurance services, as well as part sales and retail merchandise sale. It also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. In addition, the company engages in the design, manufacture, installation, sale, and leasing of solar energy gen
- Latest public price/reference: $367.2
- Public market capitalization: $1450.12B
- Recent public volume/reference: 30.87M
- One-month public movement: 2.84%
- Sector/category: Consumer Cyclical
Why TSLA Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
COIN Public Research Bio
Name: Coinbase Global, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Coinbase Global, Inc. operates platform for crypto assets in the United States and internationally. It provides the primary financial account in the crypto economy for consumers; a brokerage platform with a pool of liquidity across the crypto marketplace for institutions; and a suite of products granting access to build onchain for developers. The company was founded in 2012 and is based in New York, New York.
- Latest public price/reference: $172.9
- Public market capitalization: $45.61B
- Recent public volume/reference: 6.98M
- One-month public movement: -1.18%
- Sector/category: Financial Services
Why COIN Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
ABOS Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bear. Public tier: Extended.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Latest public price/reference: $1.745
- Public market capitalization: $126.19M
- Recent public volume/reference: 620.80K
- One-month public movement: -43.71%
- Sector/category: Healthcare
Why ABOS Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bear. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- No fresh public headlines were available from the automated outside-source pull. The asset r[redacted]ins covered through public status data.
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Selling section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.